EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state

Yuri Teranishi-Ikawa, Tetsuhiro Soeda, Hikaru Koga, Kazuki Yamaguchi, Kazuki Kato, Keiko Esaki, Kentaro Asanuma, Miho Funaki, Mina Ichiki, Yuri Ikuta, Shunsuke Ito, Eri Joyashiki und 17 weitere

Journal of Thrombosis and Haemostasis · 2024

DOI: 10.1016/j.jtha.2023.09.034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2024. Verfasst von Yuri Teranishi-Ikawa und 28 weiteren Autor:innen. Beteiligte Einrichtung: Research Division, Chugai Pharmaceutical Co, Ltd, Yokohama, Kanagawa, Japan. Hauptthemen laut MEDLINE: Hemophilia A, Hemostatics, Antibodies, Bispecific. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chugai Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Emicizumab, a factor (F) VIIIa-function mimetic bispecific antibody (BsAb) to FIXa and FX, has become an indispensable treatment option for people with hemophilia A (PwHA). However, a small proportion of PwHA still experience bleeds even under emicizumab prophylaxis, as observed in the long-term outcomes of clinical studies. A more potent BsAb may be desirable for such patients. OBJECTIVES: To identify a potent BsAb to FIXa and FX, NXT007, surpassing emicizumab by in vitro and in vivo evaluation. METHODS: New pairs of light chains for emicizumab's heavy chains were screened from phage libraries, and subsequent antibody optimization was performed. For in vitro evaluation, thrombin generation assays were performed with hemophilia A plasma. In vivo hemostatic activity was evaluated in a nonhuman primate model of acquired hemophilia A. RESULTS: NXT007 exhibited an in vitro thrombin generation activity comparable to the international standard activity of FVIII (100 IU/dL), much higher than emicizumab, when triggered by tissue factor. NXT007 also demonstrated a potent in vivo hemostatic activity at approximately 30-fold lower plasma concentrations than emicizumab's historical data. In terms of dose shift between NXT007 and emicizumab, the in vitro and in vivo results were concordant. Regarding pharmacokinetics, NXT007 showed lower in vivo clearance than those shown by typical monoclonal antibodies, suggesting that the Fc engineering to enhance FcRn binding worked well. CONCLUSION: NXT007, a potent BsAb, was successfully created. Nonclinical results suggest that NXT007 would have a potential to keep a nonhemophilic range of coagulation potential in PwHA or to realize more convenient dosing regimens than emicizumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AHemostaticsAntibodies, BispecificHumansThrombinHemostasisBlood CoagulationFactor VIII

Stichwörter der Autor:innen

NXT007bispecific antibodyemicizumabhemophilia Anonfactor replacement therapy

Substanzen

HemostaticsThrombinAntibodies, BispecificFactor VIII

Autor:innen und Institutionen

  • Research Division, Chugai Pharmaceutical Co, Ltd, Yokohama, Kanagawa, Japan.
  • Research Division, Chugai Pharmaceutical Co, Ltd, Yokohama, Kanagawa, Japan. Electronic address: koga.hikaru78@chugai-pharm.co.jp.
  • Translational Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.
  • Research Division, Chugai Pharmaceutical Co, Ltd, Yokohama, Kanagawa, Japan; Translational Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.

Förderung

  • Chugai Pharmaceutical

Zitieren

APA

Teranishi-Ikawa, Y., Soeda, T., Koga, H., Yamaguchi, K., Kato, K., Esaki, K., Asanuma, K., Funaki, M., Ichiki, M., Ikuta, Y., Ito, S., Joyashiki, E., Komatsu, S. I., Muto, A., Nishimura, K., Okuda, M., Sanada, H., Sato, M., Shibahara, N., …, & Igawa, T. (2024). A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2023.09.034

Vancouver

Teranishi-Ikawa Y, Soeda T, Koga H, Yamaguchi K, Kato K, Esaki K, et al. A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state. Journal of Thrombosis and Haemostasis. 2024. doi:10.1016/j.jtha.2023.09.034

BibTeX
@article{TeranishiIkawa2024,
  author = {Teranishi-Ikawa, Yuri and Soeda, Tetsuhiro and Koga, Hikaru and Yamaguchi, Kazuki and Kato, Kazuki and Esaki, Keiko and Asanuma, Kentaro and Funaki, Miho and Ichiki, Mina and Ikuta, Yuri and Ito, Shunsuke and Joyashiki, Eri and Komatsu, Shun-Ichiro and Muto, Atsushi and Nishimura, Kei and Okuda, Momoko and Sanada, Hisakazu and Sato, Motohiko and Shibahara, Norihito and Wakabayashi, Tetsuya and Yamaguchi, Koji and Matsusaki, Akiko and Sampei, Zenjiro and Shiraiwa, Hirotake and Konishi, Hiroko and Kawabe, Yoshiki and Hattori, Kunihiro and Kitazawa, Takehisa and Igawa, Tomoyuki},
  title = {A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2024},
  doi = {10.1016/j.jtha.2023.09.034}
}
Kostenlos starten →